ROPEGINTERFERON

Clinical trials for ROPEGINTERFERON explained in plain language.

Never miss a new study

Get alerted when new ROPEGINTERFERON trials appear

Sign up with your email to follow new studies for ROPEGINTERFERON, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1

Experimental combo targets genetic weakness in aggressive blood cancers

Disease control Not yet recruiting

This study tests adding ropeginterferon alfa-2b to the standard drug azacitidine for people newly diagnosed with a type of blood cancer (MDS or AML) that has a specific genetic change called a TP53 mutation. The goal is to find the safest dose of the combination and see if it can…

Matched conditions: ROPEGINTERFERON

Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 14:00 UTC

ROPEGINTERFERON

Get alerted when new ROPEGINTERFERON trials appear

Experimental combo targets genetic weakness in aggressive blood cancers